China: 2020’s Biggest Biotech IPO in Profile
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
Address: 27 Chao Qian Road,
Changping District Beijing, 102200, China
Tel: -69722764
Web: http://www.zhongsheng.com.cn/en/index.asp
BioSino Bio-technology and Science Inc, founded in 1988, is a leading high-technology enterprise whose major national controlling stakeholders comprise the Chinese Academy of Sciences, Beijing Municipal Government and Shanghai Municipal Government. Biosino has already become the largest manufacturer of IVD reagents in China after 20 years development.BioSino successfully finished IPO in GEM of Hong Kong Stock in 2006, symbolizing that she has marched away for her globalization, grouping and synthesis of running both products and capital. Now, Biosino has 90 IVD products, more than 200 formats including biochemistry diagnostic reagents, immunology diagnostic reagents and rapid tests. Lots of our products have got CE mark and more products are in the process of application. Now, BioSino has developed over 600 distributors and retailers over the country, occupy 75% of the Chinese market. Moreover, we have exported to over 20 countries from Southeast Asia, Middle-east, North Africa, and South America.In order to ensure consistently high quality, BioSino built a new GMP standard plant (11000m2) and established a microcomputer-controlled automated production line to achieve a completely sealed, sterile, temperature and humidity controlled environment. At the same time, meticulous and experienced employees are hired for quality control, technological safeguards and production operations. Each step is strictly in accordance with the requirements of quality control standards ISO9001:2000 and ISO13485:2003.BioSino has a professional after sales service team comprising experts in the field of biochemistry, immunology, pharmacy and medicine. We provide on-the-spot technological support and service to our customers, teach them how to use our products and resolve problems they meet. Our commitment is to provide the best service at the first moment.Looking into the future, BioSino will keep on developing new products to meet the demands of international markets. Our aim is to become a leading diagnostic manufacturer in the world and create a better future together with our partners and customers.
Bio Chemistry Reagents
Immunology Reagents
Rapid Testing Diagnostics
Diagnostic Instruments
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company.…
The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4…
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as…
Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic,…
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent…
Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth.…
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.…
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
See our Cookie Privacy Policy Here
